AltimmuneALT
ALT
About: Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Employees: 59
0
Funds holding %
of 6,815 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
39% more call options, than puts
Call options by funds: $11.8M | Put options by funds: $8.53M
26% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 46
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
3% less funds holding
Funds holding: 173 [Q2] → 167 (-6) [Q3]
6.29% less ownership
Funds ownership: 62.01% [Q2] → 55.72% (-6.29%) [Q3]
15% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 26
17% less capital invested
Capital invested by funds: $292M [Q2] → $243M (-$49.7M) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
93%
upside
Avg. target
$18.67
200%
upside
High target
$26
317%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Stifel Annabel Samimy 29% 1-year accuracy 4 / 14 met price target | 189%upside $18 | Buy Initiated | 8 Jan 2025 |
HC Wainwright & Co. Patrick Trucchio 36% 1-year accuracy 58 / 161 met price target | 93%upside $12 | Buy Reiterated | 14 Nov 2024 |
UBS Eliana Merle 16% 1-year accuracy 3 / 19 met price target | 317%upside $26 | Buy Initiated | 12 Nov 2024 |
Financial journalist opinion
Based on 4 articles about ALT published over the past 30 days
Positive
Seeking Alpha
2 weeks ago
Altimmune Could Find A Partner For Its Phase 3 Exercise
ALT's end-of-phase 2 meeting with the FDA provided a clear clinical plan for pemvidutide, but the phase 3 program will require 5,000 patients. ALT's $139M in cash is enough to stay afloat for a while at the current rate, but not to fund phase 3, the company needs a partner or a buyout. If ALT can't find a partner or be acquired, then a hefty fund raise awaits investors, which could hit the stock.
Positive
The Motley Fool
3 weeks ago
Why Altimmune Was Such a Robustly Healthy Stock on Thursday
Altimmune (ALT 3.54%) had some encouraging news to share with the world as the trading week drew near a close on Thursday. The biotech announced that it will soon ascend to an important, specialized stock index; investors greeted this news by trading the company's stock up by more than 3% on the day.
Neutral
GlobeNewsWire
3 weeks ago
Altimmune Added to Nasdaq Biotechnology Index
GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) effective prior to the market open on Monday, December 23, 2024.
Positive
Seeking Alpha
4 weeks ago
Altimmune 2025: Redefining Obesity And MASH Treatment
Altimmune is entering both obesity and MASH markets with a powerful GLP-1/Glucagon dual-agonist drug called Pemvidutide, offering fat-specific weight loss and muscle preservation with a strong safety profile. Altimmune is redefining success in both obesity and MASH to position Pemvidutide in "blue ocean" categories not addressed by incumbents and catered to the unique strengths of Glucagon in Pemvidutide. Valuation of on-label and off-label use of Pemvidutide across all indications and comorbidities show that Altimmune is significantly undervalued at current share prices, factoring in all risks.
Positive
CNBC Television
1 month ago
Altimmune CEO on what's next for its experimental obesity drug
Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, potential commercial partnership and more.
Positive
Zacks Investment Research
1 month ago
Altimmune Stock Up More Than 25% in a Month: Here's Why
ALT's recent progress related to the development of the lead product candidate, pemvidutide, for treating obesity and MASH is aiding the stock.
Neutral
GlobeNewsWire
1 month ago
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:
Neutral
CNBC Television
1 month ago
Final Trade: C, NVDA, XLF, ALT
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Neutral
GlobeNewsWire
2 months ago
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids
Positive
Seeking Alpha
2 months ago
Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge
Results from the phase 2b IMPACT study, using Pemvidutide for the treatment of patients with MASH, expected Q2 of 2025. The global metabolic dysfunction-associated steatohepatitis market size is expected to reach $7.64 billion by 2031. Successful EOP2 meeting with FDA, of Pemvidutide for treatment of patients with obesity, brings about four phase 3 trial initiations in the coming year.
Charts implemented using Lightweight Charts™